Merus, Bicara Present Promising HNSCC Trial Data at ASCO 2025, Advance Towards Phase III Published on July 9, 2025 at 12:55 am by Maham Fatima in News ...

Get today's Bicara Therapeutics stock news. We cover the latest Bicara Therapeutics headlines and breaking news impacting Bicara Therapeutics stock performance.

Dr. Mazumdar currently serves as the founding Chief Executive Officer of Bicara Therapeutics (NASDAQ:BCAX), a clinical-stage oncology company. Her appointment comes as Relay prepares to initiate its ...

Angus Liu breaks down phase 3 data on Enhertu from AstraZeneca and Daiichi Sankyo, while Gabrielle Masson overviews Bicara Therapeutics' investigational asset for head and neck squamous cell ...

Following Merus’ splash last month with a “best-in-disease profile” for its head and neck cancer bispecific, Bicara touted positive results for its monocolonal antibody, but analysts say Merus still ...

Bicara Therapeutics presented data from an ongoing, 28-patient trial of its drug showing median overall survival of over 21 months, more than double that of Keytruda.

On the opening day of the 2025 NCAA baseball tournament, four No. 4 seeds defied the odds and upset the No. 1 seeds on their home turf. Here's how it happened.

ASCO25: Merus wins in head-to-head with Bicara for head and neck cancer Petosemtamab is projected to reach $1.2bn in global sales by 2030, while ficerafusp alfa will reach $620 million.

Pelajari cara mengekspresikan diri Anda saat berbicara tentang mengubah kebiasaan.

Randomized phase I trial of adjuvant personalized cancer vaccine TG4050 in resected locally advanced (LA) head and neck squamous cell carcinoma (HNSCC) patients (pts). This is an ASCO Meeting Abstract ...